fat loss
Quality Rating
Buy Survodutide 10mg
Boehringer Ingelheim GLP-1/Glucagon dual agonist — potent NASH and fat loss data
18.7% weight loss Phase 2NASH regressionGLP-1/Glucagon dual
Who This Is For
Users seeking dual-agonist fat loss potency, particularly those with fatty liver disease (NASH) who benefit from the hepatic fat-clearing glucagon component.
Overview & Benefits
Survodutide (BI 456906) is one of the most advanced GLP-1/Glucagon dual agonists in clinical development, with Phase 2 results showing up to 18.7% body weight reduction at 48 weeks alongside marked NASH regression. The glucagon component specifically drives hepatic fat clearance — making Survodutide particularly effective for users with fatty liver disease alongside obesity.
For users without NASH, Survodutide delivers potent fat loss via combined appetite suppression and thermogenesis. The once-weekly subcutaneous injection profile mirrors semaglutide in convenience while delivering dual-agonist potency. Positioned between tirzepatide and retatrutide in terms of mechanism complexity.
Key Benefits
- Up to 18.7% body weight reduction in Phase 2 at 48 weeks
- Potent NASH regression — glucagon drives hepatic fat clearance
- Once-weekly injection — same convenience as semaglutide
- Thermogenic advantage of glucagon receptor activation
- Strong lipid profile improvements alongside fat loss
Protocols & Dosing
Weekly Titration Protocol
Once weeklyStart 0.3mg, titrate to 3–6mg over 16 weeks
Careful titration essential — GI side effects more pronounced than semaglutide. Titrate no faster than every 4 weeks.
Buy Survodutide 10mg
$159.99
Buy Now — $159.99Buy at PhiogenResearch-grade · COA verified · Phiogen
Categoryfat loss
Typeinjectable
Quality Rating★★★★☆
VendorPhiogen
Also Needed
Survodutide 10mg
$159.99